NR 566 Final Exam Qs & Ans
(Verified Answers)
Advanced Pharmacology for Care of the Family
Latest Update
Chamberlain University - MSN / NP Program
Comprehensive 145-Question Final Exam - Family-Focused Advanced Pharmacology
Section Subject Area Questions
Section 1 Pharmacokinetics & Pharmacodynamics Across the Lifespan Q1 - Q14
Section 2 Pharmacogenomics & Individualized Prescribing Q15 - Q27
Section 3 Cardiovascular Pharmacology Q28 - Q46
Section 4 Endocrine Pharmacology Q47 - Q64
Section 5 Respiratory & Allergy Pharmacology Q65 - Q78
Section 6 Anti-Infective Pharmacology Q79 - Q95
Section 7 Psychopharmacology Across the Lifespan Q96 - Q111
Section 8 Pain Management & Anti-Inflammatory Agents Q112 - Q127
Section 9 Special Populations & Prescribing Considerations Q128 - Q145
NR 566 Advanced Pharmacology for Care of the Family - 145 Questions - Verified Answers
Aligned with Chamberlain MSN Advanced Pharmacology Curriculum and 2026/2027 Clinical Practice Guidelines
,NR 566 Advanced Pharmacology for Care of the Family | Final Exam Qs & Ans | Latest 2026/2027 (Verified Answers) Edition 2026/2027
NR 566 Final Exam Qs & Ans (Verified
Answers)
Advanced Pharmacology for Care of the Family
Latest Update
This final examination presents 145 practice questions aligned with the NR 566 Advanced Pharmacology for Care of the
Family curriculum at Chamberlain University. The exam covers nine content domains in advanced pharmacology: (1)
Pharmacokinetics and Pharmacodynamics Across the Lifespan; (2) Pharmacogenomics and Individualized Prescribing; (3)
Cardiovascular Pharmacology; (4) Endocrine Pharmacology; (5) Respiratory and Allergy Pharmacology; (6) Anti-Infective
Pharmacology; (7) Psychopharmacology Across the Lifespan; (8) Pain Management and Anti-Inflammatory Agents; and (9)
Special Populations and Prescribing Considerations. Each question is multiple choice with one verified correct answer;
rationales include pharmacokinetic principles, pharmacodynamic mechanisms, current clinical practice guidelines, and
patient-specific considerations across pediatric, adult, pregnant/lactating, and geriatric populations. Approximately 75% of
questions are scenario-based requiring clinical application of pharmacologic principles; 25% test direct recall of drug
classifications and mechanisms. The 2026/2027 update reflects current FDA approvals, clinical practice guidelines
(ACC/AHA, ADA, GINA, GOLD, ATS/IDSA, APA, CDC), Beers Criteria 2023, and evidence-based prescribing standards.
Section 1
Section 1: Pharmacokinetics and Pharmacodynamics Across the Lifespan
(Absorption, Distribution, Metabolism, Excretion, Receptors, & Therapeutic
Index)
Questions: Q1 - Q14 | Focus: First-pass effect, Vd, half-life, steady state, protein binding, agonist/antagonist, therapeutic
index, pediatric/geriatric PK/PD
Q1: A patient receives a medication orally, but only 30% of the dose reaches systemic circulation due to
extensive metabolism in the liver. This phenomenon is best described as:
A. Renal clearance
B. First-pass effect reducing bioavailability [CORRECT]
C. Volume of distribution
D. Steady-state accumulation
Correct Answer: B
Rationale: The first-pass effect describes hepatic metabolism of orally administered drugs before they reach systemic
circulation, reducing bioavailability. Choice A describes renal elimination. Choice C (Vd) describes drug distribution. Choice D
occurs after ~4-5 half-lives of repeated dosing.
Q2: A drug has a volume of distribution (Vd) of 5 L. This indicates the drug is:
A. Widely distributed in tissues
B. Confined primarily to the plasma (intravascular space) [CORRECT]
C. Highly protein-bound in muscle
Chamberlain University - Advanced Practice Nursing Page 2
, D. Filtered rapidly by the kidneys
Correct Answer: B
Rationale: A Vd of ~5 L approximates plasma volume, indicating the drug remains largely in the intravascular space (e.g.,
large/charged molecules, highly protein-bound). Choice A would have a very high Vd (e.g., 200+ L). Choice C and D are not
implied by a low Vd.
Q3: A medication has a half-life of 12 hours. Approximately how long will it take to reach steady state
with repeated dosing?
A. 12 hours
B. 24 hours
C. 48 hours
D. 60 hours (~5 half-lives) [CORRECT]
Correct Answer: D
Rationale: Steady state is reached after approximately 4-5 half-lives of repeated dosing. For a drug with a 12-hour half-life,
steady state is reached at ~48-60 hours. Choice A, B, and C are insufficient dosing durations.
Q4: A drug with a narrow therapeutic index requires close monitoring. Which combination of
parameters is most critical for safety?
A. Volume of distribution and bioavailability
B. Peak and trough drug levels (e.g., vancomycin trough 15-20 mg/L for serious MRSA infections)
[CORRECT]
C. Half-life and protein binding
D. First-pass metabolism and renal clearance
Correct Answer: B
Rationale: Drugs with a narrow therapeutic index (e.g., vancomycin, aminoglycosides, digoxin, warfarin) require
therapeutic drug monitoring with peak/trough levels to maintain efficacy while avoiding toxicity. Choices A, C, and D are
general PK parameters that do not directly guide dose adjustment at the bedside.
Q5: Which pharmacokinetic change is most characteristic of geriatric patients compared with younger
adults?
A. Increased hepatic blood flow causing faster Phase I metabolism
B. Decreased renal function (lower GFR) reducing clearance of renally-eliminated drugs such as digoxin
and gabapentin [CORRECT]
C. Increased gastric acid production enhancing absorption of weak bases
D. Higher albumin levels increasing protein binding
Correct Answer: B
Rationale: Aging reduces renal function (creatinine clearance declines ~1 mL/min/year after age 40), leading to
accumulation of renally-cleared drugs (digoxin, gabapentin, allopurinol, lithium) requiring dose adjustment. Choice A is
wrong (hepatic Phase I declines). Choice C is wrong (gastric acid decreases with age). Choice D is wrong (albumin typically
decreases or stays stable in elderly).
Q6: Phase II hepatic metabolism involves:
A. CYP450-mediated oxidation/reduction
B. Conjugation reactions (glucuronidation, sulfation, acetylation) generally producing more
water-soluble metabolites [CORRECT]
, C. Active transport across the canalicular membrane
D. Renal tubular secretion
Correct Answer: B
Rationale: Phase II metabolism involves conjugation (glucuronidation by UGTs, sulfation, acetylation, glutathione
conjugation) creating polar, water-soluble metabolites for renal/biliary excretion. Phase II is relatively preserved in older
adults compared with Phase I. Choice A describes Phase I. Choice C and D describe transport/excretion.
Q7: A patient with severe hypoalbuminemia (albumin 1.8 g/dL) is taking phenytoin (highly
protein-bound). Which statement is most accurate?
A. Total phenytoin level will underestimate free active drug
B. Total phenytoin level will overestimate free active drug; therapeutic range must be adjusted
downward [CORRECT]
C. Phenytoin metabolism is increased
D. Free phenytoin fraction decreases
Correct Answer: B
Rationale: With hypoalbuminemia, less drug is bound and free (active) fraction rises. A 'normal' total phenytoin level (10-20
mg/L) may correspond to toxic free levels; the corrected therapeutic range must be adjusted downward (using the
Sheiner-Tozer formula). Choice A is reversed. Choice C is wrong. Choice D is wrong (free fraction increases).
Q8: A drug that binds to a receptor and produces a maximal response is best classified as:
A. Partial agonist
B. Competitive antagonist
C. Full agonist (high intrinsic activity) [CORRECT]
D. Inverse agonist
Correct Answer: C
Rationale: A full agonist binds to the receptor and produces the maximal possible response (high efficacy and intrinsic
activity). A partial agonist (A) produces submaximal response. A competitive antagonist (B) blocks but does not activate. An
inverse agonist (D) produces effects opposite to agonists by stabilizing inactive conformation.
Q9: A drug with an ED50 of 5 mg and an LD50 of 500 mg has a therapeutic index (TI) of:
A. 10
B. 50
C. 100 [CORRECT]
D. 500
Correct Answer: C
Rationale: Therapeutic Index = LD50 / ED50 = = 100. A higher TI indicates greater relative safety. Drugs with TI
near 1 (e.g., digoxin, warfarin) require close monitoring. Choice A (10) is wrong. Choice B (50) is wrong. Choice D (500) is
wrong.
Q10: Compared with adults, neonates and infants generally have:
A. Higher gastric acidity, accelerating absorption of weak acids
B. Higher total body water and reduced plasma protein binding, increasing Vd of water-soluble drugs
[CORRECT]
C. Mature hepatic Phase I metabolism
D. Mature renal function at birth
(Verified Answers)
Advanced Pharmacology for Care of the Family
Latest Update
Chamberlain University - MSN / NP Program
Comprehensive 145-Question Final Exam - Family-Focused Advanced Pharmacology
Section Subject Area Questions
Section 1 Pharmacokinetics & Pharmacodynamics Across the Lifespan Q1 - Q14
Section 2 Pharmacogenomics & Individualized Prescribing Q15 - Q27
Section 3 Cardiovascular Pharmacology Q28 - Q46
Section 4 Endocrine Pharmacology Q47 - Q64
Section 5 Respiratory & Allergy Pharmacology Q65 - Q78
Section 6 Anti-Infective Pharmacology Q79 - Q95
Section 7 Psychopharmacology Across the Lifespan Q96 - Q111
Section 8 Pain Management & Anti-Inflammatory Agents Q112 - Q127
Section 9 Special Populations & Prescribing Considerations Q128 - Q145
NR 566 Advanced Pharmacology for Care of the Family - 145 Questions - Verified Answers
Aligned with Chamberlain MSN Advanced Pharmacology Curriculum and 2026/2027 Clinical Practice Guidelines
,NR 566 Advanced Pharmacology for Care of the Family | Final Exam Qs & Ans | Latest 2026/2027 (Verified Answers) Edition 2026/2027
NR 566 Final Exam Qs & Ans (Verified
Answers)
Advanced Pharmacology for Care of the Family
Latest Update
This final examination presents 145 practice questions aligned with the NR 566 Advanced Pharmacology for Care of the
Family curriculum at Chamberlain University. The exam covers nine content domains in advanced pharmacology: (1)
Pharmacokinetics and Pharmacodynamics Across the Lifespan; (2) Pharmacogenomics and Individualized Prescribing; (3)
Cardiovascular Pharmacology; (4) Endocrine Pharmacology; (5) Respiratory and Allergy Pharmacology; (6) Anti-Infective
Pharmacology; (7) Psychopharmacology Across the Lifespan; (8) Pain Management and Anti-Inflammatory Agents; and (9)
Special Populations and Prescribing Considerations. Each question is multiple choice with one verified correct answer;
rationales include pharmacokinetic principles, pharmacodynamic mechanisms, current clinical practice guidelines, and
patient-specific considerations across pediatric, adult, pregnant/lactating, and geriatric populations. Approximately 75% of
questions are scenario-based requiring clinical application of pharmacologic principles; 25% test direct recall of drug
classifications and mechanisms. The 2026/2027 update reflects current FDA approvals, clinical practice guidelines
(ACC/AHA, ADA, GINA, GOLD, ATS/IDSA, APA, CDC), Beers Criteria 2023, and evidence-based prescribing standards.
Section 1
Section 1: Pharmacokinetics and Pharmacodynamics Across the Lifespan
(Absorption, Distribution, Metabolism, Excretion, Receptors, & Therapeutic
Index)
Questions: Q1 - Q14 | Focus: First-pass effect, Vd, half-life, steady state, protein binding, agonist/antagonist, therapeutic
index, pediatric/geriatric PK/PD
Q1: A patient receives a medication orally, but only 30% of the dose reaches systemic circulation due to
extensive metabolism in the liver. This phenomenon is best described as:
A. Renal clearance
B. First-pass effect reducing bioavailability [CORRECT]
C. Volume of distribution
D. Steady-state accumulation
Correct Answer: B
Rationale: The first-pass effect describes hepatic metabolism of orally administered drugs before they reach systemic
circulation, reducing bioavailability. Choice A describes renal elimination. Choice C (Vd) describes drug distribution. Choice D
occurs after ~4-5 half-lives of repeated dosing.
Q2: A drug has a volume of distribution (Vd) of 5 L. This indicates the drug is:
A. Widely distributed in tissues
B. Confined primarily to the plasma (intravascular space) [CORRECT]
C. Highly protein-bound in muscle
Chamberlain University - Advanced Practice Nursing Page 2
, D. Filtered rapidly by the kidneys
Correct Answer: B
Rationale: A Vd of ~5 L approximates plasma volume, indicating the drug remains largely in the intravascular space (e.g.,
large/charged molecules, highly protein-bound). Choice A would have a very high Vd (e.g., 200+ L). Choice C and D are not
implied by a low Vd.
Q3: A medication has a half-life of 12 hours. Approximately how long will it take to reach steady state
with repeated dosing?
A. 12 hours
B. 24 hours
C. 48 hours
D. 60 hours (~5 half-lives) [CORRECT]
Correct Answer: D
Rationale: Steady state is reached after approximately 4-5 half-lives of repeated dosing. For a drug with a 12-hour half-life,
steady state is reached at ~48-60 hours. Choice A, B, and C are insufficient dosing durations.
Q4: A drug with a narrow therapeutic index requires close monitoring. Which combination of
parameters is most critical for safety?
A. Volume of distribution and bioavailability
B. Peak and trough drug levels (e.g., vancomycin trough 15-20 mg/L for serious MRSA infections)
[CORRECT]
C. Half-life and protein binding
D. First-pass metabolism and renal clearance
Correct Answer: B
Rationale: Drugs with a narrow therapeutic index (e.g., vancomycin, aminoglycosides, digoxin, warfarin) require
therapeutic drug monitoring with peak/trough levels to maintain efficacy while avoiding toxicity. Choices A, C, and D are
general PK parameters that do not directly guide dose adjustment at the bedside.
Q5: Which pharmacokinetic change is most characteristic of geriatric patients compared with younger
adults?
A. Increased hepatic blood flow causing faster Phase I metabolism
B. Decreased renal function (lower GFR) reducing clearance of renally-eliminated drugs such as digoxin
and gabapentin [CORRECT]
C. Increased gastric acid production enhancing absorption of weak bases
D. Higher albumin levels increasing protein binding
Correct Answer: B
Rationale: Aging reduces renal function (creatinine clearance declines ~1 mL/min/year after age 40), leading to
accumulation of renally-cleared drugs (digoxin, gabapentin, allopurinol, lithium) requiring dose adjustment. Choice A is
wrong (hepatic Phase I declines). Choice C is wrong (gastric acid decreases with age). Choice D is wrong (albumin typically
decreases or stays stable in elderly).
Q6: Phase II hepatic metabolism involves:
A. CYP450-mediated oxidation/reduction
B. Conjugation reactions (glucuronidation, sulfation, acetylation) generally producing more
water-soluble metabolites [CORRECT]
, C. Active transport across the canalicular membrane
D. Renal tubular secretion
Correct Answer: B
Rationale: Phase II metabolism involves conjugation (glucuronidation by UGTs, sulfation, acetylation, glutathione
conjugation) creating polar, water-soluble metabolites for renal/biliary excretion. Phase II is relatively preserved in older
adults compared with Phase I. Choice A describes Phase I. Choice C and D describe transport/excretion.
Q7: A patient with severe hypoalbuminemia (albumin 1.8 g/dL) is taking phenytoin (highly
protein-bound). Which statement is most accurate?
A. Total phenytoin level will underestimate free active drug
B. Total phenytoin level will overestimate free active drug; therapeutic range must be adjusted
downward [CORRECT]
C. Phenytoin metabolism is increased
D. Free phenytoin fraction decreases
Correct Answer: B
Rationale: With hypoalbuminemia, less drug is bound and free (active) fraction rises. A 'normal' total phenytoin level (10-20
mg/L) may correspond to toxic free levels; the corrected therapeutic range must be adjusted downward (using the
Sheiner-Tozer formula). Choice A is reversed. Choice C is wrong. Choice D is wrong (free fraction increases).
Q8: A drug that binds to a receptor and produces a maximal response is best classified as:
A. Partial agonist
B. Competitive antagonist
C. Full agonist (high intrinsic activity) [CORRECT]
D. Inverse agonist
Correct Answer: C
Rationale: A full agonist binds to the receptor and produces the maximal possible response (high efficacy and intrinsic
activity). A partial agonist (A) produces submaximal response. A competitive antagonist (B) blocks but does not activate. An
inverse agonist (D) produces effects opposite to agonists by stabilizing inactive conformation.
Q9: A drug with an ED50 of 5 mg and an LD50 of 500 mg has a therapeutic index (TI) of:
A. 10
B. 50
C. 100 [CORRECT]
D. 500
Correct Answer: C
Rationale: Therapeutic Index = LD50 / ED50 = = 100. A higher TI indicates greater relative safety. Drugs with TI
near 1 (e.g., digoxin, warfarin) require close monitoring. Choice A (10) is wrong. Choice B (50) is wrong. Choice D (500) is
wrong.
Q10: Compared with adults, neonates and infants generally have:
A. Higher gastric acidity, accelerating absorption of weak acids
B. Higher total body water and reduced plasma protein binding, increasing Vd of water-soluble drugs
[CORRECT]
C. Mature hepatic Phase I metabolism
D. Mature renal function at birth
